Summary
Bristol Myers Squibb Company (BMY) announced significant leadership changes and reported the outcomes of its Annual Meeting of Shareholders held on May 2, 2023. The most notable development is the appointment of Dr. Christopher Boerner as Chief Operating Officer effective April 26, 2023, and his subsequent appointment as Chief Executive Officer effective November 1, 2023. Dr. Boerner has also been elected to the Board of Directors, increasing its size to twelve members. While he is a key executive, the Board has determined he is not independent under NYSE standards and will not serve on any Board committees, nor will he receive compensation for his director role. The Annual Meeting also saw shareholders re-elect all eleven incumbent directors, approve the compensation of named executive officers on an advisory basis, and vote for an annual advisory vote on executive compensation. Additionally, Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2023. However, shareholder proposals regarding an independent Board Chairperson and improvements to special shareholder meetings did not pass.
Key Highlights
- 1Christopher Boerner appointed Chief Operating Officer (COO) effective April 26, 2023, and will become Chief Executive Officer (CEO) on November 1, 2023.
- 2Dr. Boerner elected to the Board of Directors, increasing its size to twelve members.
- 3Dr. Boerner is not considered an independent director and will not serve on any Board committees.
- 4All 11 incumbent director nominees were re-elected by shareholders.
- 5Shareholders approved the advisory vote on executive compensation ('Say-on-Pay') with an annual frequency.
- 6Deloitte & Touche LLP ratified as the independent auditor for 2023.
- 7Shareholder proposals for an independent Board Chairperson and special meeting improvements were not approved.